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Abstract
Background: A peptide vaccine was produced containing B and T cell epitopes from the V3 and C4 Envelope domains of 4
subtype B HIV-1 isolates (MN, RF, CanO, & Ev91). The peptide mixture was formulated as an emulsion in incomplete Freund’s
adjuvant (IFA).
Methods: Low-risk, healthy adult subjects were enrolled in a randomized, placebo-controlled dose-escalation study, and
selected using criteria specifying that 50% in each study group would be HLA-B7+. Immunizations were scheduled at 0, 1,
and 6 months using a total peptide dose of 1 or 4 mg. Adaptive immune responses in16 vaccine recipients and two placebo
recipients after the 2nd immunization were evaluated using neutralization assays of sera, as well as ELISpot and ICS assays of
cryopreserved PBMCs to assess CD4 and CD8 T-cell responses. In addition,
51Cr release assays were performed on fresh
PBMCs following 14-day stimulation with individual vaccine peptide antigens.
Results: 24 subjects were enrolled; 18 completed 2 injections. The study was prematurely terminated because 4 vaccinees
developed prolonged pain and sterile abscess formation at the injection site-2 after dose 1, and 2 after dose 2. Two other
subjects experienced severe systemic reactions consisting of headache, chills, nausea, and myalgia. Both reactions occurred
after the second 4 mg dose. The immunogenicity assessments showed that 6/8 vaccinees at each dose level had detectable
MN-specific neutralizing (NT) activity, and 2/7 HLA-B7+ vaccinees had classical CD8 CTL activity detected. However, using
both ELISpot and ICS, 8/16 vaccinees (5/7 HLA-B7+) and 0/2 controls had detectable vaccine-specific CD8 T-cell responses.
Subjects with moderate or severe systemic or local reactions tended to have more frequent T cell responses and higher
antibody responses than those with mild or no reactions.
Conclusions: The severity of local responses related to the formulation of these four peptides in IFA is clinically
unacceptable for continued development. Both HIV-specific antibody and T cell responses were induced and the magnitude
of response correlated with the severity of local and systemic reactions. If potent adjuvants are necessary for subunit
vaccines to induce broad and durable immune responses, careful, incremental clinical evaluation is warranted to minimize
the risk of adverse events.
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Development of an effective vaccine for HIV-1 remains a public
health priority, and a recent report of partial efficacy suggests that
it may be possible [1]. The Phase III trial in Thailand evaluated a
recombinant canarypox vector expressing Envelope, Gag, and
parts of Pol and Nef proteins from HIV-1 subtype B/E in
combination with a recombinant HIV-1 B/E gp120 formulated in
alum [1]. Although the mechanism of protection is currently
unknown, the results of this study and experience gained from
other successful viral vaccine development efforts suggest that both
antibody and T cell responses will be important for preventing or
controlling HIV-1 infection.
In this study, a polyvalent synthetic peptide was evaluated in
healthy adults. It was designed to stimulate CD4 T-cells against a
conserved region of the HIV-1 Envelope glycoprotein and to elicit
both antibody and CD8 T-cell responses to the V3 loop region.
The vaccine included peptide sequences from 4 different HIV-1
clade B variants (MN, Can0A, RF, and EV91) (Table 1), and was
formulated with incomplete Freund’s adjuvant (IFA). Montanide
ISA-51 is a water-in-oil emulsion composed of mineral oil mixed
with the surfactant mannose mono-oleate in a 1:1 ratio with the
aqueous phase. The primary study objective was to assess safety,
and secondary objectives involved immunogenicity assessment of
both humoral and cellular responses. Preclinical studies with this
peptide formulation in mice and nonhuman primates demonstrat-
ed immunogenicity, including high titer antibody responses to V3,
lymphoproliferative responses indicative of CD4 T-cell responses,
and CD8 T-cell responses [2,3], and did not demonstrate
significant toxicity or local reactogenicity.
Other peptide-based vaccines for HIV have achieved variable
immunogenicity ranging from virtually no detectable responses to
an orally administered octameric HIV-1 V3 peptide in alum [4],
to consistent antibody and T cell responses detected in subjects
immunized with lipopeptide-conjugated peptides [5], to interme-
diate responses in subjected immunized parenterally repeatedly
with the octameric V3 peptide [6]. These peptide-based vaccines
all were described as having acceptable local toxicity.
Although vaccines formulated with mineral oil have been
administered to more than 1 million people since 1945, with the
emergence of aluminum-based adjuvants, they fell out of favor
because of the reactogenicity profile and potential for causing
sterile abscesses [7]. With improvements in recent generations of
IFA products that have more specific surfactants and refined oils
that reduce the frequency of local and systemic adverse events, the
use of these potent water-in-oil adjuvant formulations was adopted
for immunotherapeutic vaccines for fatal diseases including HIV-1
infection. Two peptide-based vaccines, including the one being
evaluated in the current study, formulated with Montanide ISA-51
have previously been evaluated in a total of 18 HIV-infected
subjects as candidate therapeutic vaccines [8,9], and judged to be
safe. The Montanide ISA-51 adjuvant was also evaluated in other
therapeutic vaccine trials in more than 100 HIV-infected subjects,
formulated with whole inactivated virus and was judged to be safe
[10,11]. Montanide ISA-51 has also been frequently used as an
adjuvant in a variety of therapeutic cancer vaccines in which
reactogenicity is never described as greater than moderate or
Grade 2. Therefore, in human subjects who have underlying
conditions that may affect immune competence, reactogenicity
does not appear to be a limiting factor.
In healthy adults without underlying conditions there is a mixed
history of reactogenicity from IFA, which has been extensively
reviewed, with the conclusion that for serious infections like
malaria and HIV, the use of IFA may be justified [12]. Since the
current study was undertaken, another trial has been conducted in
healthy adults evaluating safety and immunogenicity of Montanide
ISA-51 formulated with a candidate malaria vaccine comprised of
Pfs25 and Psv25 surface proteins [13]. This malaria study team
had been informed about the results of the current study. This trial
was prematurely terminated due to unexpected systemic reacto-
genicity. Six subjects experienced severe local reactions involving
swelling and induration at the injection site, which were not
unexpected based on the results of the current study. In 5 of the 6
subjects, the reaction subsided within 8 weeks, and in the other it
resolved in about 6 months. Unexpectedly, in the malaria vaccine
study, 2 out of 30 vaccine recipients developed erythema nodosum
Table 1. Subject demographics.
Control (N=3) 1 mg (N=12) 4 mg (N=9) Total (N=24)
Gender
Female 14 4 9
Male 28 5 1 5
HLA
B7 16 3 1 0
Other 26 6 1 4
Race/Ethnicity
White, non-Hispanic 21 2 7 2 1
Black, non-Hispanic 00 1 1
Asian/Pacific Islander 10 1 2
Age
Median 25 33 44 33
Range 18–29 18–44 21–58 18–58
Received Vaccine
Day 0 39 1 2 2 4
Day 30 28 8 1 8
doi:10.1371/journal.pone.0011995.t001
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report our experience with Montanide ISA-51 IFA formulated
with HIV peptide antigens, to inform future investigations of this
adjuvant in healthy adult volunteers.
Methods
Ethics Statement
These studies were approved by the Institutional Review Boards
(IRB) at each clinical site (Vanderbilt University IRB, University of
Rochester IRB, and Fred Hutchinson Cancer Research Center
IRB), and were performed in accordance with 45 CFR Part 46,
U.S. Food and Drug Administration regulations, and principles
expressed in the Declaration of Helsinki. All subjects signed
written informed consent documents.
Objectives
The purpose of the study was to evaluate the safety and
immunogenicity of a polyvalent HIV-1 C4-V3 synthetic peptide
mixture formulated in Incomplete Freund’s Adjuvant (IFA,
mineral oil containing mannose mono-oleate). Four synthetic
peptides based on the HIV-1 clade B strains MN, EV91, RF, and
CANO are included in the candidate vaccine. Each of these four
component peptides consists of two sections or parts. The first, the
‘‘C4’’ section, is a 15 amino acid sequence corresponding to a
potent activator of anti-HIV memory helper T cells present in the
fourth conserved region of HIV-1 gp120. The second part, the
‘‘V3’’ section, is a 24 amino acid sequence which corresponds to
the V3 loop region of gp120 of the particular HIV-1 strain. The
V3 region is an established B cell epitope recognized by anti-HIV
neutralizing antibodies, as well as being an HLA-B7 restricted
CTL epitope. The same ‘‘C4’’ sequence 15 is used in all four of the
pooled fusion peptides, while the V3 portion of the fusion peptide
is unique for each strain. The trial was sized to achieve the
primary objective which was to evaluate the safety of the C4-V3
peptides formulated in IFA in HIV-1 uninfected volunteers, and
secondary objectives were to evaluate the humoral and cellular
immune responses. The protocol for this trial and supporting
CONSORT checklist are available as supporting information; see
Checklist S1, Diagram S1, Protocol S1.
Study design
Healthy adult volunteers between 18 and 60 years of age were
eligible for enrollment. The study was randomized, placebo-
controlled and double-blind. Statisticians assigned the randomi-
zation sequence to the pharmacy using a random number
generator. Clinicians, subjects, and laboratory investigators were
all blinded to the assignments. The goal was to enroll 28 subjects,
half of whom had the HLA-B7 allele known to present the V3
epitope contained in the vaccine [14]. 12 subjects would receive a
total of 1 mg peptide (250 mg of each); 12 would receive 4 mg
peptide (1 mg of each); and 4 would receive the placebo
preparation which was adjuvant alone without peptide. Subjects
were scheduled to receive 4 injections at 0, 1, 6, and 12 months.
Subjects were injected with 0.5 ml in both arms. After each
immunization, subjects were observed for 30 minutes and
monitored for temperature and local reactions. Subjects recorded
their own temperature daily for 3 days and recorded any signs and
symptoms. Each subject was seen on either day 1 or 2 post vaccine
in the clinic and contacted by phone on day 7 to review the
symptoms during the immediate post-vaccination period. Labo-
ratory evaluations including urinalysis, alanine transaminase
(ALT), gamma-glutamyl transpeptidase (GGT), creatinine, CBC
with differential counts and platelets, and CD4/CD8 T cell counts
were assessed prevaccination, 4 weeks following the first
vaccination, and 2, 4 and 24 weeks following the second
vaccination. Subjects were originally scheduled to be followed
for an additional 6 months following the month 12 injection. DTH
skin testing was done in a subset of subjects at day 378. See
Protocol S1 for additional details including specific inclusion and
exclusion criteria (Pages 13–14).
The study was approved by the U.S. Food and Drug
Administration and registered with ClinicalTrials.gov
(#NCT00000886). The local Institutional Review Board of each
participating site approved the study, and a Data and Safety
Monitoring Committee provided oversight, in addition to the site
clinicians and the protocol safety team that included a Division of
AIDS medical monitor.
Vaccine Preparation and Delivery
The four peptide sequences are shown in Table S1. Peptide
immunogens were manufactured and quality controlled by a
commercialvendorforFDAINDsubmissionandapproval.Peptides
were mixed in equal concentrations and combined with Montanide
ISA-51usingtheKirklandEmulsiFlex1000
TMdevice.Theemulsion
stability was confirmed with the ‘‘water-drop’’ test. This test was
performed in a 60615 mm petri dish containing 4uC water. After
preparing the sterile syringe for vaccine administration, one drop of
the remaining emulsion was dropped from 1 cm above the water
with the syringe held at a 60u angle. To meet the criteria for a stable
emulsion, the drop had to remain intact on the water surface for
3 minutes. If the emulsion was acceptable, it was delivered as a
0.5 ml injection into each deltoid muscle. For additional details see
Appendix D in the protocol posted in Protocol S1 online. The
placebo control was Montanide ISA-51without peptide.
Antibody responses
Neutralizing antibodies were assessed against HIV-1MN in an
MT-2 cell-killing assay as described [15]. Briefly, 500 TCID50 of
virus were incubated with multiple dilutions of heat-inactivated
serum samples in triplicate for 1 hr at 37uC in 96-well flat-bottom
culture plates. Cells (5610
4) in 100 ml of growth medium were
added and the incubation continued until most but not all of the
cells in virus control wells (cells+virus but no serum sample) were
involvedinsyncytiumformation(usually3-5days).Cellviabilitywas
quantified by neutral red uptake [15]. Neutralization titers were
defined as the reciprocal serum dilution (before the addition of cells)
at which 50% of cells are protected from virus induced killing. Each
set of assays included a positive control serum that had been assayed
multiple times and had a known average titer. The assay stock of
HIV-1MN was grown in H9 cells and titrated in MT-2 cells.
T cell responses
The measurements of CD8+ T cell function were performed by
the AVEG Central Laboratory at Duke University. The lytic assay
was performed with fresh PBMCs using a standard 4-hour
51Cr-
release assay. Effectors were stimulated with peptides for 14 days
and targets were peptide-labeled autologous BLCL. IFN-c ELI-
Spot assays were performed after 16-hour peptide stimulation of
2610
5 cryopreserved PBMCs. Positive responses were defined as a
3-fold response above background and .2-fold reduction
following depletion of CD8+ T cells as described [16]. Intracel-
lular IFN-c production was analyzed by flow cytometry after 6-
hour peptide stimulation. CD33+CD62P expression was used to
exclude monocytes and activated platelets, and final analysis plots
of IFN-c-APC vs. CD69-PE were gated on CD4
+ or CD8
+
lymphocytes. Background gates were set at 0.05%, and positive
results were defined as .2-fold background.
HIV-1 Peptide Vaccine in IFA
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Descriptive summaries with frequencies of reactogenicity
measures, immune assay response rates and geometric mean titer
results are presented along with nonparametric comparisons of
antibody levels and reaction severity. An exact 2-sided 95%
confidence interval for the rate of sterile abscess or delayed local
reaction is calculated.
Results
Twenty-four of the projected 28 study participants were
enrolled at three sites (Rochester, NY, Nashville, TN and Seattle,
WA) between 10/13/1997 and 03/05/1998. There were 15 male
and 9 female participants; 21 were White, 1 was Black and 3 were
Asian/Pacific Islanders. The median participant age was 33 years
(range 18–58). Four participants had the HLA A2 haplotype and
10 had HLA B7. All 24 participants received the first study
vaccination; 18 received the second. Two participants withdrew
after the first vaccination and were lost to follow-up; 4 participants
did not receive the second vaccination due to discontinuation of
vaccination as described below (Table 1).
Local reactogenicity
Reactogenicity was evaluated in the immediate post-vaccination
period by self-reported diary cards. Local reactogenicity assess-
ments included pain, tenderness, induration, and erythema.
During the first 7 days after each vaccination there was nothing
unusual about the local reactions (Table 2). In four subjects (2
receiving 1 mg and 2 receiving 4 mg), painful swelling developed
over both deltoids beginning between 1 week and 2 months after
vaccination. The swelling included induration and central
erythema, and subjects often woke from sleep because of the
pain. In two subjects the painful swelling occurred after the first
dose, and they did not receive the second vaccination. In both of
these subjects the lesions resolved spontaneously without drainage.
The other two developed the lesions after the second vaccination;
one received the 1 mg dose and the other received the 4 mg dose.
In these subjects, the induration, pain, and swelling increased until
spontaneous drainage occurred between 10 and 11 weeks post-
vaccination. The lesions over the right and left arms in one subject
spontaneously drained within one day of each other. In the other
subject, the spontaneous drainage in one arm was followed by
aspiration and incision and drainage of the other arm 12 weeks
later. Once drainage was established, the lesions gradually resolved
and healed, in one case leaving a hyperpigmented scar (Figure 1,
Table S2). These were all sterile abscesses, and no pathogenic
organisms were isolated from any of the lesions or exudates. In
summary, sterile abscesses were observed in 4/21 treated subjects,
19.1% (95% CI 6.8% to 39.8%), after which further vaccinations
were terminated by joint recommendation of the study investiga-
tors and safety oversight committee.
Systemic reactogenicity
Systemic reactogenicity self-assessments were done for 3 days
after each vaccination and included malaise, myalgia, headache,
fever, chills, and nausea (Table 3). Severe systemic reactions began
between 2 and 6 hours post-immunization. The most severe
systemic reactions occurred in the 4 mg dose group and after the
second immunization. The symptoms were characterized by
sudden onset of headache, chills, nausea, and myalgia. The
symptoms resolved in 24–48 hours. None of the subjects with the
delayed sterile abscess formation had moderate or severe systemic
reactogenicity. There were no significant or notable hematologic,
renal, or hepatic abnormalities in any of the subjects at any time
during the study.
Antibody response
All 20 vaccine recipients who remained in follow-up had
detectable ELISA antibody responses to at least one peptide at day
196, and nine of 20 (45%) remained positive at day 378. None of
the subjects had a detectable ELISA antibody response to
gp160IIIB. The peak frequency of ELISA antibody to the MN
V3 peptide was 13/20 (65%) at day 196. 75% of subjects had low
level neutralizing activity against HIV-1MN (Table 4). At day 56,
ELISA antibody responses were assessed to V3 peptides from
Can0, EV91, MN, and RF, and to full length gp160. The
magnitude of the antibody response measured by OD tended to
correlate with the severity of reactogenicity. Comparing subjects
with moderate or severe (n=10) local or systemic reactions to
those with no reactions or mild (n=11) yielded respective
Wilcoxon test p-values of .07, .17, .06, and .06 for the Can0,
EV91, MN, and RF V3 responses The association appeared to be
related primarily to systemic reactions since the rank correlations
were significant between systemic grade reactions for 3 of the V3
peptides and no trends toward correlation were observed for any
antigen with the severity of local reactions.
T cell responses
One subject in each of the active dose groups had a detectable
CD8 T-cell response measure by
51Cr-release at day 42, 14 days
after the second immunization. Both subjects were HLA-B7+.
Both of those subjects also had positive CD8 ELISpot responses.
Those 2 subjects and 3 other HLA-B7+ vaccinees had positive
CD8 ICS responses. Therefore, of those who received two
immunizations, a total of 5/7 HLA-B7+ subjects had evidence
of vaccine-induced CD8 T-cell responses, while only 3 of 9 HLA-
B7-negative subjects had detectable CD8 T cell responses
(Table 5). Six of the 8 CD8 T cell responders had moderate or
Table 2. Local reactions* within 7 days of vaccination.
Vaccination #1 Vaccination #2
N None{ Mild Moderate Severe N None Mild Moderate Severe
1m g 1 2 1 9 2 0 8 1 6 1 0
4m g 9 1 4 4 0 8 0 5 3 0
control 3 0 3 0 0 2 1 1 0 0
*Local reactions included: pain, tenderness, erythema, induration.
{None=no pain or tenderness; Mild=minimal pain or tenderness, no limitation of arm use; Moderate=notable pain or tenderness, some limitation of use of arm;
Severe=extreme pain or tenderness, complete limitation of use of arm.
doi:10.1371/journal.pone.0011995.t002
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formation, while only 3/8 nonresponders had moderate systemic
reactions and no sterile abscesses. DTH skin testing showed that
7/16 vaccinees had .5 mm reaction to 10 mg of peptide mixture.
Neither of the two tested placebo recipients had positive responses.
Response rates to Candida and tetanus antigens were 9/16 and 5/
16, respectively, among vaccinees and 1/2 and 2/2 in placebo
recipients.
Discussion
We report the Phase I clinical evaluation of a peptide-based
candidate HIV vaccine formulated as an emulsion with Mon-
tanide ISA-51. The 4 peptides were designed to elicit CD4 T-cell
responses to conserved regions in Envelope, and antibody and
CD8 T-cell responses to epitopes contained in gp120 V3. To
evaluate the vaccine induction of CD8 T-cell responses, 50% of
Figure 1. Case report of local reaction and sterile abscess formation. Two days after the 1
st immunization, a 22 year old man in the 1 mg
dose cohort developed mild tenderness over the injection site that resolved on day 4. After the 2
nd immunization was administered 28 days later,
mild tenderness occurred that lasted for one day. 15 days after the 2
nd immunization a 0.25 cm asymptomatic subcutaneous nodule was detected on
routine physical exam. There was no erythema at that time. Fifty days post 2
nd immunization the volunteer reported the onset of throbbing pain and
that was treated with warm compresses and nonsteroidal anti-inflammatory drugs. On day 56 there was erythema and induration of 8 and 9 cm
diameter over the prior injection sites, and the subject was afebrile with a WBC of 9,600/cm
2. On day 63 there was less pain and the area of induration
was unchanged. However, the induration was less firm and the central area of erythema (A and B) was fluctuant. On day 84 there was spontaneous
drainage from the lesions, from multiple fistulas on the right arm (C) and a single fistula on the left (D). The clinical course of all 4 subjects with sterile
abscess formation is reviewed in Table S2.
doi:10.1371/journal.pone.0011995.g001
Table 3. Systemic reactions* within 7 days of vaccination.
Vaccination #1 Vaccination #2
N None{ Mild Moderate Severe N None Mild Moderate Severe
1m g 1 2 6 4 2 0 8 3 2 3 0
4m g 9 6 2 1 0 8 1 2 3 2
control 3 2 1 0 0 2 1 1 0 0
*Systemic reactions included: malaise, myalgia, headache, fever, nausea.
{None=no symptoms; Mild=symptoms require no change in activity or medication; Moderate=symptoms require modification of activity or medication;
Severe=symptoms are incapacitating, requiring bed rest and/or loss of work or cancellation of social activities.
doi:10.1371/journal.pone.0011995.t003
HIV-1 Peptide Vaccine in IFA
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restriction element for the V3 (RPNNNTRKSI) CTL epitope.
This product concept was extensively characterized and in
preclinical studies was shown to elicit antibody and CD4 and
CD8 T-cell responses [8,17,18,19,20,21]. Although the product
was shown to be immunogenic after two doses in this study,
immunogenicity was not fully evaluated because the trial was
stopped early due to unacceptable local reactogenicity. Therefore,
this analysis is focused primarily on the safety endpoints of the
trial.
The primary differences between the immunotherapy studies
done with this product formulated in Montanide ISA-51 and the
current studies are: 1) the immunological health of the subjects, 2)
the 0.5 ml instead of 0.25 ml dose volume, and 3) the strength of
the emulsion created with the EmulsiFlex 1000
TM mechanical
device. In preclinical toxicity studies, the clinical product had been
tested in rabbits and rhesus monkeys. In one of two monkeys given
a series of three immunizations with an 8 mg dose of peptide,
granulomatous inflammation was noted at necropsy at the
injection site. Otherwise, there was nothing notable about local
toxicity.
The distinct differences in local reactogenicity between the
current study and the studies evaluating therapeutic vaccines in
HIV-infected subjects suggest that underlying host immune
competence may be a primary determinant of the intensity of
the local response to the Montanide ISA-51 adjuvant. This is
supported by the prolonged local reactions in the Pfs25/Pvs25
malaria vaccine study in healthy subjects [13]. Even though sterile
abscesses requiring drainage were not reported, there was
induration lasting up to 6 months. It is also supported by the
studies using this adjuvant with therapeutic vaccines for a variety
of neoplasms in which the vaccines were characterized as well-
tolerated [12,22]. Two of the subjects in the present study with the
delayed subcutaneous reactions and prolonged induration or
abscess formation had reported arm soreness from overuse at the
time of the initial vaccination (one from floor scrubbing and the
other from skiing). The role of significant arm exercise in the
subsequent reaction is unknown.
The assumption is that sterile abscess formation was related to
the inflammatory effect induced by the adjuvant. Licensed
aluminum-based adjuvants rarely are associated with sterile
abscess formation, and the cause is thought to be related to
aluminum hypersensitivity reactions [23]. The high frequency of
local reactions in this study suggests adjuvant-induced inflamma-
tion rather than hypersensitivity was the cause of abscess
formation. The adjuvant effect of IFA is in part related to the
Toll-like receptor (TLR) stimulation by products contained in the
oil, and in part by a depot effect. The removal of the vaccine dose
in a stable emulsion by professional antigen presenting cells can
take months. Therefore, using a higher dose volume would not
only enlarge the central nidus of a sterile abscess, but would
prolong the length of the inflammatory stimulus underlying the
genesis of the abscess. The volume of the vaccine dose in the HIV
therapeutic trial using this product was 0.25 ml. The dose volume
in the Pfs25/Pvs25 malaria study was 0.5 ml. Based on the
experience in this study with a 0.5 ml dose, we suggest that the
lowest possible volume needed to deliver an adequate antigen dose
should be used with potent adjuvants that have the potential for
sterile abscess formation.
The method of producing the emulsion was the major
difference between the current study and the trial done in healthy
adults with malaria antigens in which there were some prolonged
local reactions and two cases of erythema nodosum [13]. The
emulsion was intentionally produced to be stable in the current
study to reduce the potential for escape of the oils to organs like the
spleen and liver, where they could potentially serve as a stimulus
for granulomatous inflammation. One could speculate that the
erythema nodosum seen in the malaria trial was related to a
slightly less stable emulsion, and the sterile abscess formation in
this study was related to extremely high stability of the emulsion. It
is also possible that antigenic differences could explain the
differences in systemic reactogenicity between this study and the
one evaluating malaria antigens with IFA. In this study the only
severe systemic reactions occurred after the second dose in the
4 mg recipients. The rapid onset of headache, chills, nausea, and
myalgia within hours after vaccination in this study suggests the
vaccine formulation activated innate responses, but the higher
severity of reactions after the second vaccination suggests that
tissue-resident antigen-specific effectors from the first vaccination
may have also contributed to the exaggerated response. The
reason why subjects with the most severe systemic reactions did
not develop severe local reactions is not known. It is possible this
was a coincidence because of the small trial size or may reflect
something about the nature of the underlying inflammation
responsible for the local and systemic reactions.
Table 4. Antibody response on day 56 in subjects who received 2 doses.
ELISA 50% neutralization assay
Frequency (mean O.D.) Frequency and reciprocal serum dilution
Group N C4-V3 – RF* C4-V3 – MN V3 MN MN Geometric mean titer Median
IFA control 2 0/2 0/2 0/2 0/2 - -
1 mg 8 8/8 (1.03) 7/8 (0.33) 4/8 (0.46) 6/8 42 29
4 mg 8 8/8 (1.62) 6/8 (0.69) 6/8 (0.44) 6/8 41 38
*C4-V3 refers to the entire peptide antigen used in the vaccine.
doi:10.1371/journal.pone.0011995.t004
Table 5. T cell responses in subjects who received 2 doses of
vaccine.
Frequency of Positive Responses at Day 42
Group N
51Cr CTL CD8 ELISpot CD8 ICS
CD4 ELISpot
or ICS
IFA control 2 0 0 0 0
HLA-B7+ 72 2 5 3
HLA-B72 90 2 1 3
doi:10.1371/journal.pone.0011995.t005
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this product had good immunogenicity. Antibody responses were
detectable in 100% of subjects after two immunizations, which is
notable for subunit vaccines in general. T cell responses were
detected in the majority of subjects despite the early termination
and incomplete vaccination schedule and the fact that this study
was performed and analyzed during the historical period when
both cryopreservation techniques and assay methodology were in
transition. Therefore, the frequency and magnitude of the
ELISpot and ICS responses in this report may be lower than
they would have been if processed and tested with current
methodologies. This study was specifically designed to detect
HLA-B7-restricted CD8 T-cell responses to the V3 peptide
epitope (RPNNNTRKSI). The absence of a
51Cr CTL response
to this epitope in 4/6 HLA-B7+ subjects tested may be due to the
relatively low sensitivity of the assay. In contrast, 5/7 HLA-B7+
subjects had vaccine-induced CD8 T-cell responses by ICS. The
two nonresponders may have not had sufficient vaccine-induced
immune activation, the assays may have been insensitive, or there
may have been other influences related to epitope liberation,
processing, or degradation, competing responses to other epitopes,
or subject-specific response hierarchies that explain the lack of
detectable T cell responses. Three of the 9 HLA-B7-negative
subjects also had detectable CD8 T-cell responses. Two of these
subjects were HLA-A2+ and could have recognized a variant of
the RGPGRAFVTI epitope described in V3 [24], although the
exact sequence is not represented in this vaccine. The other
subject was HLA-A1, B8, and B57 and the epitope in the vaccine
that is restricted by these alleles is not known. These data suggest
that peptides can elicit CD8 CTL when formulated with a potent
adjuvant. However, it should be kept in mind that control of HIV
may require broad responses to multiple epitopes, and eliciting
potent epitope-specific CD8 T-cell responses requires more than
MHC compatibility. Therefore, restricting the antigenic content of
vaccine antigens may limit the host options for selecting and
presenting effective T cell targets and will limit the breadth of the
response.
This study, AIDS Vaccine Evaluation Group (AVEG) Protocol
020, was designed to enroll 28 subjects to evaluate two doses of the
peptide-based vaccine in IFA, but was terminated early because of
sterile abscess formation in 4 of the first 24 enrollees. While the
peptide-based vaccine was immunogenic, the local reactogenicity
was unacceptable for continued development. We show that
achieving an immunogenic peptide formulation is feasible in
humans, but it may be associated with a significant reactogenicity
cost, which in this study was unacceptable. Considering the
outcome of this study and the malaria vaccine study, future studies
using Montanide ISA-51 as an adjuvant in healthy subjects should
be carefully considered from the standpoint of both local and
systemic reactogenicity. Overly stable emulsions that may mitigate
systemic reactogenicity have the potential to cause unacceptable
local reactogenicity including chronic sterile abscesses.
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